FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CHCHD6-MYO1A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CHCHD6-MYO1A
FusionPDB ID: 16256
FusionGDB2.0 ID: 16256
HgeneTgene
Gene symbol

CHCHD6

MYO1A

Gene ID

84303

4640

Gene namecoiled-coil-helix-coiled-coil-helix domain containing 6myosin IA
SynonymsCHCM1|MICOS25|Mic25|PPP1R23BBMI|DFNA48|MIHC|MYHL
Cytomap

3q21.3

12q13.3

Type of geneprotein-codingprotein-coding
DescriptionMICOS complex subunit MIC25coiled coil helix cristae morphology 1coiled-coil-helix cristae morphology protein 1coiled-coil-helix-coiled-coil-helix domain-containing protein 6, mitochondrialmitochondrial contact site and cristae organizing system subununconventional myosin-Iabrush border myosin Imyosin I heavy chainmyosin, heavy polypeptide-like (100kD)myosin, heavy polypeptide-like 110kDa
Modification date2020032720200313
UniProtAcc

Q9BRQ6

Main function of 5'-partner protein: FUNCTION: Component of the MICOS complex, a large protein complex of the mitochondrial inner membrane that plays crucial roles in the maintenance of crista junctions, inner membrane architecture, and formation of contact sites to the outer membrane. {ECO:0000269|PubMed:22228767}.

Q9UBC5

Main function of 5'-partner protein: FUNCTION: Involved in directing the movement of organelles along actin filaments. {ECO:0000305}.
Ensembl transtripts involved in fusion geneENST idsENST00000290913, ENST00000508789, 
ENST00000515867, 
ENST00000476795, 
ENST00000300119, ENST00000442789, 
ENST00000544473, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 5 X 5=1501 X 1 X 1=1
# samples 61
** MAII scorelog2(6/150*10)=-1.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(1/1*10)=3.32192809488736
Fusion gene context

PubMed: CHCHD6 [Title/Abstract] AND MYO1A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CHCHD6 [Title/Abstract] AND MYO1A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CHCHD6(126499273)-MYO1A(57424958), # samples:1
CHCHD6(126452065)-MYO1A(57424958), # samples:1
Anticipated loss of major functional domain due to fusion event.CHCHD6-MYO1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CHCHD6-MYO1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CHCHD6-MYO1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CHCHD6-MYO1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCHCHD6

GO:0006974

cellular response to DNA damage stimulus

22228767



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:126499273/chr12:57424958)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CHCHD6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MYO1A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000290913CHCHD6chr3126452065-ENST00000300119MYO1Achr1257424958-1525504691286405
ENST00000290913CHCHD6chr3126452065-ENST00000442789MYO1Achr1257424958-1525504691286405
ENST00000290913CHCHD6chr3126452065-ENST00000544473MYO1Achr1257424958-1424504691286405
ENST00000508789CHCHD6chr3126452065-ENST00000300119MYO1Achr1257424958-1504483481265405
ENST00000508789CHCHD6chr3126452065-ENST00000442789MYO1Achr1257424958-1504483481265405
ENST00000508789CHCHD6chr3126452065-ENST00000544473MYO1Achr1257424958-1403483481265405

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000290913ENST00000300119CHCHD6chr3126452065-MYO1Achr1257424958-0.0120958040.98790425
ENST00000290913ENST00000442789CHCHD6chr3126452065-MYO1Achr1257424958-0.0120958040.98790425
ENST00000290913ENST00000544473CHCHD6chr3126452065-MYO1Achr1257424958-0.013749640.9862504
ENST00000508789ENST00000300119CHCHD6chr3126452065-MYO1Achr1257424958-0.012335160.9876649
ENST00000508789ENST00000442789CHCHD6chr3126452065-MYO1Achr1257424958-0.012335160.9876649
ENST00000508789ENST00000544473CHCHD6chr3126452065-MYO1Achr1257424958-0.0141403380.9858597

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CHCHD6-MYO1A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CHCHD6chr3126452065MYO1Achr1257424958483145GSISHEEQKSVRLVQKFLLGLKNNLP
CHCHD6chr3126452065MYO1Achr1257424958504145GSISHEEQKSVRLVQKFLLGLKNNLP

Top

Potential FusionNeoAntigen Information of CHCHD6-MYO1A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CHCHD6-MYO1A_126452065_57424958.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:05VRLVQKFLL0.99990.81321019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:04VRLVQKFLL0.99990.74611019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:01KSVRLVQKF0.99960.8961817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B58:02KSVRLVQKF0.9990.8301817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:03KSVRLVQKF0.99860.9451817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B15:17KSVRLVQKF0.99830.845817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B50:02EEQKSVRLV0.99770.5845514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B15:16KSVRLVQKF0.99760.6212817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B45:01EEQKSVRLV0.99730.8028514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B58:01KSVRLVQKF0.99690.8097817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B39:24VRLVQKFLL0.99240.59291019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B14:02VRLVQKFLL0.98820.841019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B14:01VRLVQKFLL0.98820.841019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-A32:13KSVRLVQKF0.97560.8391817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-A30:08SVRLVQKFL0.94860.6513918
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B44:03EEQKSVRLV0.91630.9528514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B41:01EEQKSVRLV0.88770.8317514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B13:01KSVRLVQKF0.26270.8668817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:01QKSVRLVQKF0.98240.9181717
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:03QKSVRLVQKF0.93970.9318717
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B51:07EQKSVRLV0.97670.7103614
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:14VRLVQKFLL0.99990.75131019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:95VRLVQKFLL0.99910.66231019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:05VRLVQKFLL0.9990.95521019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:27VRLVQKFLL0.99880.9441019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:03VRLVQKFLL0.99710.85411019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C15:04KSVRLVQKF0.99430.7454817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:46VRLVQKFLL0.99360.87091019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:19VRLVQKFLL0.99060.70411019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B39:12VRLVQKFLL0.96880.9081019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C12:12KSVRLVQKF0.65590.8074817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C12:04KSVRLVQKF0.52470.9743817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B51:07EEQKSVRLV0.27810.7798514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:08VRLVQKFLL0.99990.68441019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:10VRLVQKFLL0.99990.86831019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:06VRLVQKFLL0.99990.72831019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:09VRLVQKFLL0.99980.79441019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:10KSVRLVQKF0.99960.8961817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:01VRLVQKFLL0.99940.66891019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B58:06KSVRLVQKF0.9990.7276817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:04KSVRLVQKF0.99870.5987817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-A32:01KSVRLVQKF0.99650.8141817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C15:09KSVRLVQKF0.99430.7454817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:02KSVRLVQKF0.99040.8172817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-A30:01SVRLVQKFL0.95630.7436918
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C15:02KSVRLVQKF0.95590.7533817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C06:08VRLVQKFLL0.94220.98771019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B44:26EEQKSVRLV0.91630.9528514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B44:13EEQKSVRLV0.91630.9528514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B44:07EEQKSVRLV0.91630.9528514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B15:24KSVRLVQKF0.90310.8553817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B41:03EEQKSVRLV0.88190.5785514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C07:22VRLVQKFLL0.88090.69621019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C16:02KSVRLVQKF0.86660.981817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B18:03EEQKSVRLV0.69070.8165514
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C02:02KSVRLVQKF0.37430.9528817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C02:10KSVRLVQKF0.37430.9528817
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C06:17VRLVQKFLL0.31740.99121019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-C06:02VRLVQKFLL0.31740.99121019
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B57:10QKSVRLVQKF0.98240.9181717
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B27:09SVRLVQKFLL0.95270.7517919
CHCHD6-MYO1Achr3126452065chr1257424958504HLA-B15:12EQKSVRLVQKF0.99760.6803617

Top

Potential FusionNeoAntigen Information of CHCHD6-MYO1A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CHCHD6-MYO1A_126452065_57424958.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1113QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1113EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1117QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1152QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1189QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1377QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1377EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1377EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1401QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1401EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1401EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1404QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1404EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1404EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1405QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1408QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1411QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1411EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1411EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1418QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1423QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1426QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1426EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1426EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1428QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1428EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1428EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1431QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1431EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1431EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1432QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1432EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1432EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1434QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1435QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1435EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1435EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1438QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1439QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1439EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1443QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1445QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1445EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1445EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1450QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1450EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1450EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1454QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1454EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1454EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1455QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1455EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1455EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1456QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1458QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1458EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1458EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1459QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1460QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1460EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1460EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1461QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1461EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1461EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1462QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1462EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1464QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1464EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1464EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1465QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1465EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1465EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1468QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1470QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1471QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1471EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1471EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1472QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1472EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1472EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1475QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1475EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1481QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1482QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1482EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1482EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1486QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1486EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1486EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1487QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1487EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1487EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1488QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1488EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1488EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1490QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1490EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1490EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1491QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1495QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1496QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1497QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1497EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1497EQKSVRLVQKFLLGL621
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1499QKSVRLVQKFLLGLK722
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1499EEQKSVRLVQKFLLG520
CHCHD6-MYO1Achr3126452065chr1257424958504DRB1-1499EQKSVRLVQKFLLGL621

Top

Fusion breakpoint peptide structures of CHCHD6-MYO1A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
2055EQKSVRLVQKFLLGCHCHD6MYO1Achr3126452065chr1257424958504

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CHCHD6-MYO1A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN2055EQKSVRLVQKFLLG-7.15543-7.26883
HLA-B14:023BVN2055EQKSVRLVQKFLLG-4.77435-5.80965
HLA-B52:013W392055EQKSVRLVQKFLLG-6.80875-6.92215
HLA-B52:013W392055EQKSVRLVQKFLLG-4.20386-5.23916
HLA-A11:014UQ22055EQKSVRLVQKFLLG-7.5194-8.5547
HLA-A11:014UQ22055EQKSVRLVQKFLLG-6.9601-7.0735
HLA-A24:025HGA2055EQKSVRLVQKFLLG-7.52403-7.63743
HLA-A24:025HGA2055EQKSVRLVQKFLLG-5.82433-6.85963
HLA-B27:056PYJ2055EQKSVRLVQKFLLG-3.28285-4.31815
HLA-B44:053DX82055EQKSVRLVQKFLLG-5.91172-6.94702
HLA-B44:053DX82055EQKSVRLVQKFLLG-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of CHCHD6-MYO1A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CHCHD6-MYO1Achr3126452065chr12574249581019VRLVQKFLLGTCCGGCTGGTACAGAAATTCCTACTG
CHCHD6-MYO1Achr3126452065chr1257424958514EEQKSVRLVGAGGAGCAGAAGTCAGTCCGGCTGGTA
CHCHD6-MYO1Achr3126452065chr1257424958614EQKSVRLVGAGCAGAAGTCAGTCCGGCTGGTA
CHCHD6-MYO1Achr3126452065chr1257424958617EQKSVRLVQKFGAGCAGAAGTCAGTCCGGCTGGTACAGAAATTC
CHCHD6-MYO1Achr3126452065chr1257424958717QKSVRLVQKFCAGAAGTCAGTCCGGCTGGTACAGAAATTC
CHCHD6-MYO1Achr3126452065chr1257424958817KSVRLVQKFAAGTCAGTCCGGCTGGTACAGAAATTC
CHCHD6-MYO1Achr3126452065chr1257424958918SVRLVQKFLTCAGTCCGGCTGGTACAGAAATTCCTA
CHCHD6-MYO1Achr3126452065chr1257424958919SVRLVQKFLLTCAGTCCGGCTGGTACAGAAATTCCTACTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CHCHD6-MYO1Achr3126452065chr1257424958520EEQKSVRLVQKFLLGGAGGAGCAGAAGTCAGTCCGGCTGGTACAGAAATTCCTACTGGGG
CHCHD6-MYO1Achr3126452065chr1257424958621EQKSVRLVQKFLLGLGAGCAGAAGTCAGTCCGGCTGGTACAGAAATTCCTACTGGGGCTG
CHCHD6-MYO1Achr3126452065chr1257424958722QKSVRLVQKFLLGLKCAGAAGTCAGTCCGGCTGGTACAGAAATTCCTACTGGGGCTGAAG

Top

Information of the samples that have these potential fusion neoantigens of CHCHD6-MYO1A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SKCMCHCHD6-MYO1Achr3126452065ENST00000290913chr1257424958ENST00000300119TCGA-EB-A5UL-06A

Top

Potential target of CAR-T therapy development for CHCHD6-MYO1A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CHCHD6-MYO1A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CHCHD6-MYO1A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource